ProShare Advisors LLC Increases Position in Definitive Healthcare Corp. (NASDAQ:DH)

ProShare Advisors LLC boosted its holdings in shares of Definitive Healthcare Corp. (NASDAQ:DH) by 49.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,018 shares of the company’s stock after acquiring an additional 4,943 shares during the period. ProShare Advisors LLC’s holdings in Definitive Healthcare were worth $62,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Irenic Capital Management LP grew its holdings in shares of Definitive Healthcare by 9.2% during the fourth quarter. Irenic Capital Management LP now owns 7,003,194 shares of the company’s stock worth $28,783,000 after buying an additional 590,009 shares in the last quarter. Graham Capital Management L.P. grew its holdings in Definitive Healthcare by 58.5% in the fourth quarter. Graham Capital Management L.P. now owns 85,748 shares of the company’s stock valued at $352,000 after purchasing an additional 31,651 shares during the period. D. E. Shaw & Co. Inc. grew its holdings in Definitive Healthcare by 29.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 709,769 shares of the company’s stock valued at $2,917,000 after purchasing an additional 161,599 shares during the period. Bayesian Capital Management LP purchased a new stake in Definitive Healthcare in the fourth quarter valued at approximately $41,000. Finally, BNP Paribas Financial Markets purchased a new stake in Definitive Healthcare in the fourth quarter valued at approximately $313,000. Institutional investors and hedge funds own 98.67% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on DH shares. BTIG Research downgraded Definitive Healthcare from a “buy” rating to a “neutral” rating in a research report on Friday, May 9th. Barclays decreased their price objective on shares of Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating for the company in a research note on Monday, March 3rd. The Goldman Sachs Group raised their price objective on Definitive Healthcare from $3.00 to $3.40 and gave the company a “neutral” rating in a research report on Monday, May 12th. Finally, Wall Street Zen cut Definitive Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Definitive Healthcare has a consensus rating of “Hold” and an average price target of $5.10.

Definitive Healthcare Trading Up 6.7%

Definitive Healthcare stock opened at $3.49 on Wednesday. The firm’s 50-day moving average is $2.88 and its 200-day moving average is $3.76. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49. Definitive Healthcare Corp. has a 1 year low of $2.15 and a 1 year high of $6.27. The company has a market cap of $518.76 million, a P/E ratio of -1.13, a PEG ratio of 4.06 and a beta of 1.48.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The company had revenue of $59.19 million for the quarter, compared to the consensus estimate of $56.20 million. During the same period last year, the firm posted $0.08 EPS. The company’s revenue for the quarter was down 6.8% on a year-over-year basis. On average, equities analysts expect that Definitive Healthcare Corp. will post 0.16 earnings per share for the current year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.